Welcome to our dedicated page for CURANEX PHARMACEUTICALS SEC filings (Ticker: CURX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Curanex Pharmaceuticals Inc. SEC filings document a development-stage pharmaceutical issuer advancing botanical drug programs, led by Phyto-N. Its disclosures include Regulation FD reports on pipeline focus, preclinical and regulatory-development topics, and formal updates involving cancer cachexia and inflammatory-disease indications.
The company’s filings also cover Nasdaq continued-listing notices, common-stock capital structure, unregistered equity issuances, IPO-related share activity, related-party promissory notes, executive employment agreements, compensatory arrangements and governance matters. Periodic-report records include Form 12b-25 late-filing notices for quarterly reporting obligations.
Curanex Pharmaceuticals (CURX) reported a Nasdaq notice that its common stock failed the $1.00 minimum bid price requirement for 30 consecutive business days. Trading on the Nasdaq Capital Market continues under “CURX”.
The company has a 180‑day compliance period until May 4, 2026 to regain compliance by having a closing bid of at least $1.00 for a minimum of ten consecutive business days (subject to Nasdaq staff discretion). If unmet, Curanex may receive an additional 180 days if it satisfies other initial listing standards and notifies Nasdaq of an intent to cure, which may include a reverse stock split. Failing that, the stock would be subject to delisting.
Curanex Pharmaceuticals Inc reported two key actions. The company issued 28,312 unregistered shares of common stock to investor Xiaohong Song under a prior subscription agreement, in exchange for $200,000 that had been subscribed contingent on its initial public offering. This share grant represents 0.1% of 28,312,500 total common shares outstanding at the time of issuance and was made under a private offering exemption.
Curanex also fully repaid two insider loans from Dian Ying Jing, the CEO’s spouse, totaling $400,000 of principal. It paid $408,537.32 in aggregate, including $8,537.32 of accrued interest at a 4.34% annual rate, and did so ahead of the 2027 maturity dates. This prepayment eliminated all of the company’s outstanding debt and removed approximately $26,182.68 of future interest charges that would have accrued through maturity.